Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.

CONCLUSIONS: HDR monotherapy delivered as two fraction of 13.5 Gy is well tolerated with a high cancer control rate at 5 years. Single fraction monotherapy is inferior and should not be used. PMID: 32146259 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32146259?dopt=Abstract

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - March 4, 2020 Category: Radiology Authors: Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, Cheung P, Szumacher E, Liu S, Chu W, Zhang L, Mamedov A, Loblaw A Tags: Radiother Oncol Source Type: research